Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Sex Dev ; 17(1): 1-7, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36626890

RESUMO

BACKGROUND: Persistent müllerian duct syndrome (PMDS) is characterized by the persistence of müllerian duct derivatives in otherwise normally virilized 46,XY males. Biallelic mutations of the anti-müllerian hormone (AMH) and AMH receptor type 2 (AMHR2) genes lead to PMDS type 1 and 2, respectively. AIM: The aims of the study were to report the clinical, hormonal, and genetic findings in a patient with PMDS and discuss surgical strategies to achieve successful orchidopexy. RESULTS: A 4-year-old boy was evaluated after the incidental finding of müllerian derivates during laparoscopy for nonpalpable gonads. Karyotype was 46,XY and laboratory tests revealed normal serum gonadotropin and androgen levels but undetectable serum AMH levels. PMDS was suspected. Molecular analysis revealed a novel variant c.902_929del in exon 5 and a previously reported mutation (c.367C>T) in exon 1 of the AMH gene. Successful orchidopexy was performed in two sequential surgeries in which the müllerian duct structure was preserved and divided to protect the vascular supply to the gonads. Histological evaluation of the testicular biopsy showed mild signs of dysgenesis. Doppler ultrasound showed blood flow in both testes positioned in the scrotum 1.5 years after surgery. CONCLUSION: PMDS is a rare entity that requires a high index of suspicion (from surgeons) when evaluating a patient with bilateral cryptorchidism. Surgical treatment is challenging and long-term follow-up is essential. Histological evaluation of the testis deserves further investigation.


Assuntos
Transtorno 46,XY do Desenvolvimento Sexual , Laparoscopia , Masculino , Humanos , Pré-Escolar , Hormônio Antimülleriano/genética , Transtorno 46,XY do Desenvolvimento Sexual/genética , Transtorno 46,XY do Desenvolvimento Sexual/cirurgia , Transtorno 46,XY do Desenvolvimento Sexual/diagnóstico , Mutação/genética
2.
J Pediatr Endocrinol Metab ; 35(1): 19-27, 2022 Jan 27.
Artigo em Inglês | MEDLINE | ID: mdl-34674406

RESUMO

Pediatric adrenocortical tumors are rare and heterogeneous endocrine malignancies. OBJECTIVES: To report clinical, biochemical, and histological features, staging, and therapeutic interventions in a cohort of 28 patients treated at a single tertiary center. METHODS: A retrospective review of medical records of children with PACT (diagnosed before <18 years of age) followed between 1987-2018 at Hospital de Pediatría Garrahan, Buenos Aires, Argentina. RESULTS: Mean age at diagnosis was 4.6 years (range, 0.3-17.3 years) and median follow-up was 4.17 years (range, 0-12 years). Female to male ratio was 2.5:1. Signs and symptoms that prompted medical intervention were hormonal overproduction (57%), abdominal complaints (36%), and hypertensive encephalopathy (7%). In patients with clinically virilizing tumors (n=16) mean height standard deviation score (SDS) and bone age advance were significantly higher while body mass index (BMI) SDS was significantly lower than in those with clinical Cushing's (n=10) (p<0.05). Serum dehydroepiandrosterone sulfate (DHEAS) levels were significantly higher in stage IV than in stage I (p=0.03). Total adrenalectomy was performed in 26 patients. Eight patients (stage III-IV) received adjuvant chemotherapy. Five-year overall and disease-free survival were 100% for ST I-II, and 51% (95% CI 21-82) and 33% (95% CI 1.2-65) for ST III-IV, respectively (p=0.002). No statistical difference was found when comparing 2-year parameters with and without adjuvant chemotherapy. CONCLUSIONS: Height SDS and BMI SDS seem to mirror hormonal secretion in pediatric adrenocortical tumors. Higher DHEAS levels were found in patients with more advanced disease. Further large-scale studies are needed to validate a possible role for DHEAS as a biochemical marker of tumor stage and to draw robust conclusions on the use of adjuvant chemotherapy.


Assuntos
Neoplasias do Córtex Suprarrenal/terapia , Adolescente , Neoplasias do Córtex Suprarrenal/mortalidade , Neoplasias do Córtex Suprarrenal/patologia , Criança , Pré-Escolar , Sulfato de Desidroepiandrosterona/sangue , Feminino , Seguimentos , Humanos , Lactente , Masculino , Estadiamento de Neoplasias , Estudos Retrospectivos , Centros de Atenção Terciária
3.
J Clin Endocrinol Metab ; 104(10): 4323-4330, 2019 10 01.
Artigo em Inglês | MEDLINE | ID: mdl-31135894

RESUMO

CONTEXT: The low-dose (1 µg) ACTH test (LDT) is widely used to assess central adrenal insufficiency (CAI); however, the serum cortisol cutoff value is controversial. Salivary cortisol (SC) may be a more accurate measurement for CAI. OBJECTIVE: To assess a new maximum cutoff value of serum cortisol after LDT in pediatric patients, taking into account serum and SC measurements. DESIGN AND SETTING: Prospective study in a pediatric tertiary referral center. WORKING HYPOTHESIS: The combined analysis of serum and SC response to LDT might improve LDT for CAI diagnosis. PARTICIPANT AND OUTCOME MEASUREMENT: A total of 145 pediatric patients underwent LDT. Serum and SC levels were measured. A central adrenal sufficient (CAS) response was established according to the reference serum cortisol cutoff value of ≥497 nmol/L. RESULTS: The LDT study showed central adrenal sufficiency in 72 patients and CAI in 73 patients. Considering the lower quartile of maximum SC value (21 nmol/L) in the CAS group, an intermediate CAI (InCAI) group and a real CAI (RCAI) group were defined. Regarding the median maximum value of serum cortisol levels in the InCAI group, a new serum cortisol cutoff value of 450 nmol/L was established. Furthermore, 91% of the patients in the RCAI group were below this cutoff value. CONCLUSION: The combined evaluation of maximum serum and SC levels to LDT might be useful to define an InCAI group and to avoid unnecessary hormone replacement therapy. However, rigorous patient follow-up is required.


Assuntos
Insuficiência Adrenal/diagnóstico , Hormônio Adrenocorticotrópico/farmacologia , Hidrocortisona/sangue , Sistema Hipófise-Suprarrenal/fisiopatologia , Glândulas Salivares/metabolismo , Adolescente , Insuficiência Adrenal/sangue , Hormônio Adrenocorticotrópico/sangue , Criança , Estudos de Coortes , Feminino , Humanos , Masculino , Pediatria , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Estudos Prospectivos , Curva ROC , Sensibilidade e Especificidade
5.
Arch Argent Pediatr ; 115(4): 391-398, 2017 Aug 01.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-28737870

RESUMO

The acid-labile subunit (ALS) is an 85 kDa glycoprotein that belongs to the leucine-rich repeat superfamily. It mainly circulates in serum bound to a high molecular weight ternary complex. The main and most widely studied function of ALS is to prolong the half-life of the binary complex formed by insulin-like growth factors type 1 and 2 and its transport proteins 3 and 5. ALS serum levels are lower in neonates, reach a peak in late puberty, and then slowly decrease throughout adulthood. ALS deficiency has consequences on growth, hydrocarbon and bone metabolism, and, in some cases, it affects pubertal development. To date, 25 patients with complete ALS deficiency due to IGFALS gene mutations have been found.


La subunidad ácido-lábil (acid-labile subunit; ALS, por sus siglas en inglés) es una glicoproteína de 85 kiloDalton (kD) que pertenece a la superfamilia de repeticiones ricas en leucina. Principalmente, circula en suero dentro de un complejo ternario de alto peso molecular. La principal y más estudiada función de la ALS es prolongar la vida media del complejo binario que forman los factores de crecimiento insulinosímil tipo 1 y 2 con sus proteínas de transporte 3 y 5. El nivel sérico de la ALS es menor en neonatos,aumenta para llegar a un pico en la pubertad tardía y luego disminuye lentamente durante la vida adulta. Su déficit tiene consecuencias sobre el crecimiento, el metabolismo hidrocarbonado, el óseo y, en algunos casos, en el desarrollo puberal. Hasta el momento, se han encontrado 25 pacientes con déficit completo de la ALS debido a mutaciones del gen IGFALS.


Assuntos
Proteínas de Transporte/sangue , Glicoproteínas/sangue , Glicoproteínas/deficiência , Criança , Deficiências Nutricionais/sangue , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...